Global Biosurgery Market - 2021-2028
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The global biosurgery market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Biosurgery products are used in various surgeries to minimize intra and post-operative complications. Various synthetic and biologic products like anti-adhesive agents, hemostatic agents, surgical sealing agents, bone graft substitutes are utilized in surgeries to prevent excessive blood loss or provide adhesion or wound/tissue healing and repair of damaged or weakened tissues or bones of a body.
The growing need for effective blood loss management in patients is expected to drive the market's growth.
One major reason for blood loss in surgery and trauma patients is the ineffective use of traditional wound closure products, such as sutures and staples. Globally, the growing number of accidents has increased the number of surgeries that involve long operating hours. In turn, it has increased the need for effective blood loss management products during surgical procedures. According to a 2019 article published in the National Library of Medicine, uncontrolled hemorrhage is the leading cause of preventable death due to injury. Similarly, according to the National Trauma Institute, after a traumatic injury, hemorrhage is responsible for over 35% of pre-hospital deaths and over 40% of deaths within the first 24 hours of the injury. The number of surgeries that involve long operating times is increasing. In such a scenario, there is a growing demand for effective blood loss management products.
Moreover, different biosurgery products, including hemostatic agents and surgical sealants, are finding substantial adoption as a substitute for conventional sutures and staples during surgeries to control bleeding and cover the wound when conventional products are used impractical. Thus, from the above statements, due to the growing adoption of biosurgery products over conventional products, their use in effectively controlling blood loss drives the growth in the biosurgery market.
The growing number of sports injuries is expected to drive the growth of the market.
According to the John Hopkins Medicine, in 2020, some sports are more dangerous than others. For example, contact sports such as football can be expected to result in a higher number of injuries than a noncontact sport such as swimming. All types of sports have a potential for injury, whether from the trauma of contact with other players or overuse or misuse of a body part. In the U.S., about 30 million children and teens participate in organized sports, and more than 3.5 million injuries each year, which cause some loss of time of participation, are experienced by the participants. Almost one-third of all injuries incurred in childhood are sports-related injuries. By far, the most common injuries are sprains and strains.
Moreover, death from a sports injury is rare; the leading cause of death from a sports-related injury is a brain injury. Sports and recreational activities contribute to approximately 21 percent of all traumatic brain injuries among American children. Almost 50 percent of head injuries sustained in sports or recreational activities occur during bicycling, skateboarding, or skating incidents. More than 775,000 children, ages 14 and younger, are treated in hospital emergency rooms for sports-related injuries each year. Most of the injuries occurred due to falls, being struck by an object, collisions, and overexertion during unorganized or informal sports activities.
The high price of biosurgery products and the rising cost of surgical procedures are expected to hamper the market's growth.
The biosurgery market is extremely competitive in pricing, due to the high competitive intensity among existing players. Most of the products available in this market are priced at a premium. The high cost, coupled with the unfavorable reimbursement scenario for these products in emerging countries, makes them unaffordable for a large section of the target patient population. Due to the high cost of biosurgery products, conventional procedures such as sutures and ligature-based procedures are preferred during surgeries across emerging countries. Also, the biosurgery products currently available in the market are made of complicated reconstitutes with a poor shelf life. Hence, there is a growing need for low-priced products that are easy to handle and have a better shelf life.
COVID-19 Impact Analysis
The COVID-19 pandemic has affected the healthcare systems and has a notable impact on the market. The hospitals became high-risk zones, specifically for patients suffering from chronic conditions. Therefore, non-critical procedures such as elective surgeries were either canceled or postponed during the first and second parts of 2020, which resulted in a significant decline in the total number of elective surgical procedures performed. As a result, the demand for biosurgery products witnessed a sharp decline in 2020. The second wave of COVID-19 further deprioritized elective surgical procedures. Governments across the globe have also issued limitations and bans on medical procedures and elective surgeries. Moreover, the pandemic has resulted in the decline of surgical procedures and is expected to increase in the third quarter of 2021 in countries such as the US. Some countries in the EU have resumed surgical interventions, which has increased the demand for biosurgery products in the region.
Bone graft substitute segment is expected to hold the largest market share in this market segment.
The bone graft substitute segment accounted for the largest share in 2020. The segment's growth is attributed to the increasing use of bone graft substitute products in orthopedic and dental surgeries and the significant benefits offered by bone graft substitute products over conventional autograft products. For instance, according to the article(MDPI), in 2021. After tooth loss, bone resorption is irreversible, leaving the area without the adequate bone volume for successful implant treatment. Bone grafting is the only solution to reverse dental bone loss and is a well-accepted procedure required in one in every four dental implants. The various classifications of bone grafts and substitutes, including natural and synthetic materials, are critically present and available as commercial products in each category. Different bone substitute materials, including metals, ceramics, polymers, or their combinations, and their chemical, physical, and biocompatibility properties are utilized.
Moreover, the bone graft substitutes reduce the need to harvest healthy bones from patients to facilitate bone fusion in diseased or surgical bones. In comparison to autografts, the materials used for bone-graft substitutes can be sourced in sufficient quantity in the form of pellets, paste, strips, gels, putty, or blocks. Thus, the bone graft substitute segment is expected to hold the largest market share from the above statements.
Cardiovascular surgery segment is expected to hold the largest market share in this market segment.
The cardiovascular surgery segment dominated the market in 2020. The growth is attributed to the increasing number of cardiac problems and growing healthcare investment. According to the Centers for Disease Control and Prevention (CDC) 2020 data, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. Moreover, One person dies every 36 seconds in the United States from cardiovascular disease, and about 655,000 Americans die from heart disease each year-that's 1 in every 4 deaths. Therefore, an increase in cardiovascular diseases leads to an increase in cardiac surgeries in the forthcoming years. Thus, the cardiovascular surgery segment is expected to hold the largest market share from the above statements.
North America region holds the largest market share in the global biosurgery market.
North America dominated the market with a revenue share in 2020. The growth is attributed to the rising obese patients, cardiovascular diseases, and increasing number of surgeries. For instance, according to the research done by the Harvard T.H. Chan School of Public Health, it is estimated that around 40% of Americans are considered obese, and 18% are considered severely obese as of 2019. Severe obesity is defined as a BMI over 35 in the study. Their projections say that about half of the US population (48.9%) will be considered obese, and nearly 1 in 4 (24.2%) will be considered severely obese by the year 2030. Moreover, the increasing count of geriatrics and the growing healthcare industry, and the rising adoption of advanced surgical tools and devices, substantial investments by governments to strengthen public healthcare delivery are key factors augmenting the market's growth. Thus, from the above statements, the North American region holds the largest market share.
The biosurgery market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Integra Lifesciences Corporation, Baxter International Inc., Becton, Dickinson and Company, B. Braun Melsungen AG, CryoLife, Inc., Pfizer, Strykers, C.R. Bard and Sanofi. The major players are adopting several growth strategies such as Type launches, acquisitions, and collaborations, which are contributing to the growth of the Biosurgery market globally.
Biosurgery Market Key Companies to Watch
Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company principally focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. Bioscience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine and vaccines. Moreover, the medical products business produces intravenous products and other products used in delivering fluids and drugs to patients; inhalational anesthetics.
Baxter International Inc. is into the continuous offering of surgical products. For instance, TISSEEL [Fibrin Sealant] for Surgical Care.
The global biosurgery market report would provide an access to an approx. 47market data table, 45 figures and 200pages.
Global Biosurgery Market - By Product
Global Biosurgery Market - By Application
Global Biosurgery Market - By Region
LIST NOT EXHAUSTIVE